PatientsVille.com Logo

UNEVALUABLE EVENT and Dopamine

PatientsVille

UNEVALUABLE EVENT Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for UNEVALUABLE EVENT

UNEVALUABLE EVENT treatment research studies

Dopamine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Dopamine Side Effects

Renal Failure (24)
Injury (23)
Unevaluable Event (21)
Fear (20)
Pain (19)
Renal Injury (18)
Death (17)
Emotional Distress (16)
Renal Impairment (15)
Anxiety (15)
Multi-organ Failure (14)
Stress (14)
Hypotension (11)
Device Failure (11)
Anhedonia (10)
Blood Pressure Decreased (10)
Device Malfunction (9)
Cardiac Arrest (9)
Depression (7)
Cardio-respiratory Arrest (5)
Loss Of Consciousness (5)
Incorrect Dose Administered (5)
Electrocardiogram St Segment Elevation (4)
Hypernatraemia (4)
Cerebrovascular Accident (4)
Bradycardia (4)
Renal Failure Acute (4)
Myocardial Infarction (4)
Ventricular Fibrillation (4)
Ventricular Tachycardia (4)
Pulse Absent (4)
Acidosis (3)
Accidental Overdose (3)
Acute Respiratory Distress Syndrome (3)
Blood Pressure Systolic Decreased (3)
Choreoathetosis (3)
Condition Aggravated (3)
Blood Pressure Immeasurable (3)
Atrial Fibrillation (3)
Confusional State (3)
Encephalitis (3)
Depressed Level Of Consciousness (3)
Tachycardia (3)
Hypertension (3)
Metabolic Acidosis (3)
Rhabdomyolysis (3)
Mitral Valve Incompetence (3)
Nausea (2)
Pancytopenia (2)
Nervousness (2)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I m a neurotherapist. i m doing neurotherapy since 7 year. this disease is uncurable . plz tell me some advice

Shijiazhuang Kidney Disease Hospital in China is specialized in treating Diabetes and Diabetic Nephropathy. Since it was founded in 1986, it concentrates on dealing with kinds of kidney problem. In June, 2010, Stem Cell Technology is introduced to ou

Dear Medwrench, I want to share this information with you in hopes of saving someone else the pain my wife is suffering. An uncommon event happened to my wife during her Radiofrequency Ablation. My only purpose is to

I experienced a near death medical event (PE) and began acting without any care about my own health by seeking and attaing a full-time job without declaring my illness less than a month after leaving hospital, I left the job due to heart pains within

I had 14 crushed zimovave taken ini f=juice , ave aslos otaken i4 ibrifrnin = some anti depprent medicationand bit of alkahol event some nynetool ,probaoly want to die as i don not have leave before itell my mother i loved much but icantsta

I started with 50 mg back in jan 2008 and that seemed to keep what was then a once a month sometimes less event of AF the AF seemed to groing quite regular and so i reluctantly moved to 100 then during 2010 it was at 200mg. now in 2010 it get the AF

I used zeffix for a minimum period of 24 months because iwas confirmedHBsag positive. While on the prescription, i notice a lot of forgetfulness in me. b4 then i could remember an event that happened with every little details. But

I was prescribed Cardizem and Entrophen on March 16, 2011 at the Cardiology Institute in Montreal after an event. 10 days later my aryhthmic heart beats are ongoing and even more frequent. My morning blood pressure is 100/74 and my pulse is 67, but w

I went for an MRI with contrast. When the gadalinium was administered, I experienced a transient global amnesia event. I had to be taken to an ER and was admitted to the hospital. Docs insisted the gadalinium would not t

I went reluctantly against my will and now I am paying the 'heavy' price for my indicision... that other people had eventually made for me... thus suffering, now, from' the unintended consequences' of this terrible event. Ever since that fateful d

Male got zostavax vaccine age 60. Three months later diagnosed with Cutaneous Lupus and sjogren's symdrome, adverse event from zostavax. Continues to suffer, life long, with lupus and sjogrens.

My mom is in the hospital for bowel surgery, and it has been since thursday that they administerd the anesthsia, and she still had diplopia...she had a hypotensive event in the post up room, and now I read that it can cause diplopia, is that true, an

UNEVALUABLE EVENT Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Condition: Heart Failure, Diastolic
Interventions: Drug: Furosemide;   Drug: Dopamine
Outcome Measures: Change in glomerular filtration rate at 72 hours;   Change in incidence of acute kidney injury;   Volume of diuresis measured in liters;   Six minute walk distance;   Global well-being assessment score;   Heart failure readmissions;   Frailty index;   Subjective dyspnea score;   Length of stay
2 Not yet recruiting Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Condition: Traumatic Brain Injury
Interventions: Drug: methylphenidate;   Drug: Placebo
Outcome Measures: Relationship between tonic Dopamine release (measured by displacement of [11C]-raclopride by oral methylphenidate) and change in processing speed between baseline and after methylphenidate treatment.;   Relationship between D2/D3 receptor availability in ventral striatum and prefrontal cortex and neuropsychologic deficits.;   Relationship between tonic Dopamine release in the ventral striatum and prefrontal cortex with neuropsychologic deficits after TBI.;   Relationship between D2/D3 receptor availability and functional connectivity of the prefrontal cortex with nodes of the default mode network.;   Relationship between TMS-induced short-interval cortical inhibition of M1 and tonic Dopamine release.;   Test motivation and reward on and off methylphenidate in TBI patients.
3 Unknown  Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial
Condition: Acute Heart Failure
Interventions: Drug: Furosemide;   Drug: low-dose Dopamine + low-dose furosemide
Outcome Measures: 1-year mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).;   60-day mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).
4 Unknown  A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.
Condition: Tobacco Use Disorder
Intervention: Drug: Bupropion
Outcome Measures: Dopamine D2 receptor occupancy before and after smoking a cigarette with nicotine;   Subjective measures of craving, anxiety and depression.
5 Recruiting Dopamine Versus Dobutamine for Treatment of Arterial Hypotension in Term and Preterm Neonates
Condition: Arterial Hypotension
Interventions: Drug: Dobutamine;   Drug: Dopamine
Outcome Measures: Cerebral tissue oxygen saturation;   Cardiac output
6 Recruiting Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects
Conditions: Hyperglycemia;   Sepsis
Intervention: Drug: Dopamine
Outcome Measures: insulin secretion;   counter-regulatory hormones
7 Not yet recruiting Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients
Condition: Parkinson's Disease
Intervention: Behavioral: Role of Dopamine
Outcome Measures: percentage of signal modification;   Cluster activation size;   Brain activity indicators
8 Recruiting Vasopressors for Cerebral Oxygenation
Conditions: Hypoxia;   Hypotension
Interventions: Drug: Dopamine;   Drug: phenylephrine
Outcome Measures: Cerebral oximeter reading;   cardiac output;   incidence of delirium;   incidence of acute renal injury
9 Recruiting Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
Condition: Postural Orthostatic Tachycardia Syndrome
Interventions: Radiation: Total Blood Volume;   Procedure: Exercise Capacity Test - Bicycle;   Procedure: Posture Study
Outcome Measures: Urinary sodium;   Urinary Dopamine;   Blood Volume;   Change in Heart Rate with Standing;   Orthostatic Symptoms;   Change in Urinary Sodium following Change in Dietary Sodium;   Change in Urinary Dopamine following Change in Dietary Sodium
10 Not yet recruiting Switching From Oral Dopamine Agonists to Rotigotine
Conditions: Restless Legs Syndrome;   Ekbom Syndrome;   Willis-Ekbom Disease
Intervention: Drug: Rotigotine
Outcome Measures: Proportion of patients completing the switch and their adverse events;   International Restless Legs Scale (IRLS);   RLS-6 Scales;   Preference of Medication Scale (POM);   The Patient Global Impression of Change scale;   The Clinician Global Impression of Change Scale
11 Recruiting Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence
Conditions: Cocaine-Related Disorders;   Cocaine Addiction;   Substance-Related Disorders
Intervention: Drug: Corticotropin-Releasing Hormone
Outcome Measures: PET measure: [11C]-(+)-PHNO binding;   stress hormone levels;   subjective measures;   vital signs;   neuropsychological battery
12 Recruiting Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
Outcome Measures: Dopamine transporter binding potential;   Serotonin transporter binding potential;   Relationships between transporter binding potential and the clinical scores
13 Recruiting Blinking and Yawning in Epilepsy: The Role of Dopamine
Condition: Idiopathic Generalized Epilepsy
Intervention: Other: Apomorphine (Experimental product)
Outcome Measures: Number of yawn;   Number of eyelid blinking;   Number of eyelid blinking in both groups after apomorphin or placebo injection;   Neurophysiological assessment of the Dopaminergic reactivity;   To test the correlation between the behavioral and neurophysiological markers of Dopaminergic reactivity in patients with epilepsy;   To assess Dopaminergic reactivity with biological markers;   Number of Adverse Events as a Measure of Safety and Tolerability;   Check the absence of spike-wave discharges in healthy volunteers
14 Not yet recruiting The Relationship Between Traumatic Brain Injury and Dopamine (a Chemical in the Brain)
Condition: Traumatic Brain Injury
Interventions: Drug: Methylphenidate;   Drug: Placebo
Outcome Measure: Choice reaction time (CRT) task with methylphenidate in patients with low volume of distribution (VT) of the Dopamine transporter (DAT) in the striatum.
15 Recruiting Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder
Intervention: Drug: risperidone
Outcome Measures: The occupancy of risperidone at the D2 and D3 receptor, using [11C]-raclopride and [11C]-(+)-PHNO, respectively.;   Plasma levels of risperidone and 9-hydroxyrisperidone
16 Recruiting Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological and Pharmacokinetic Profiles
Conditions: Parkinson's Disease;   Secondary Behavioural Addiction
Intervention: Other: questionnaires
Outcome Measures: Psychopathological axis : score of sensation seeking (S Score) of the impulsivity questionnaire "UPPS";   Pharmacological axis : Area under the curve of the pramipexole concentration;   Neurological axis : Unified Parkinson's Disease Rating Scale (UPDRS) III score;   Treatments except the anti-parkinsonism ones;   drug misuse;   addiction and punding antecedents;   ADHD antecedents;   impulsivity profile;   Age of onset of the Parkinson's disease;   stage and form of the Parkinson's disease;   time course of Parkinson's disease;   family history of Parkinson's disease;   anti-parkinsonism treatments;   Residual plasmatic concentration of the pramipexole;   median pharmacokinetic parameters of pramipexole;   study of the hepatic and renal functions;   Physiopathological covariates
17 Recruiting Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies
Condition: Dementia With Lewy Bodies
Interventions: Other: Imaging with IBVM;   Other: Imaging with DATSCAN;   Behavioral: neuropsychological evaluation
Outcome Measures: Binding Potential (BP) quantification of each radioligand;   Ratio Dopaminergic system/cholinergic system Binding Potential
18 Unknown  Expression Profile of Somatostatin Receptors and Dopamine Receptor 2 in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vivo Response to Pasireotide and Cabergoline
Conditions: Non-functioning Pituitary Adenomas;   Prolactinomas
Interventions: Drug: Pasireotide;   Drug: cabergoline
Outcome Measures: Tumor volume reduction;   Prolactin levels normalization
19 Unknown  Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson's Disease Treated With Dopamine Agonists
Conditions: Heart Valve Diseases;   Parkinson's Disease
Intervention:
Outcome Measure:
20 Recruiting The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study
Condition: Healthy
Intervention: Drug: Prazosin Hydrochloride
Outcome Measure: Changes in [11C]-(+)-PHNO binding